2017
DOI: 10.1016/j.vph.2017.02.004
|View full text |Cite
|
Sign up to set email alerts
|

Potential benefits of eicosapentaenoic acid on atherosclerotic plaques

Abstract: Residual cardiovascular (CV) risk remains in some patients despite optimized statin therapy and may necessitate add-on therapy to reduce this risk. Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, lowers plasma triglyceride levels without raising low-density lipoprotein cholesterol levels and has potential beneficial effects on atherosclerotic plaques. Animal studies have shown that EPA reduces levels of pro-inflammatory cytokines and chemokines. In clinical trials utilizing a wide spectrum … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
52
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 71 publications
(53 citation statements)
references
References 66 publications
1
52
0
Order By: Relevance
“…These macrophages take up oxidized apolipoprotein B–containing LDL particles, a process leading to foam cell and fatty streak formation, the precursor of advanced atherosclerotic lesions. Potential beneficial effects of EPA on atherosclerotic plaque include anti‐inflammatory and antioxidant effects, decreased adhesion of monocytes to the endothelium, decreased macrophage and foam cell accumulation in fatty streaks, and increased thickness of the fibrous cap overlying lipid‐rich plaque28, 29, 30 (reviewed in Nelson et al) 31. EPA and DHA are also converted to specialized proresolving lipid mediators, with EPA and DHA being the respective precursors of the E‐series and D‐series resolvins 32.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…These macrophages take up oxidized apolipoprotein B–containing LDL particles, a process leading to foam cell and fatty streak formation, the precursor of advanced atherosclerotic lesions. Potential beneficial effects of EPA on atherosclerotic plaque include anti‐inflammatory and antioxidant effects, decreased adhesion of monocytes to the endothelium, decreased macrophage and foam cell accumulation in fatty streaks, and increased thickness of the fibrous cap overlying lipid‐rich plaque28, 29, 30 (reviewed in Nelson et al) 31. EPA and DHA are also converted to specialized proresolving lipid mediators, with EPA and DHA being the respective precursors of the E‐series and D‐series resolvins 32.…”
Section: Discussionmentioning
confidence: 99%
“…Potential beneficial effects of EPA on atherosclerotic plaque include anti-inflammatory and antioxidant effects, decreased adhesion of monocytes to the endothelium, decreased macrophage and foam cell accumulation in fatty streaks, and increased thickness of the fibrous cap overlying lipid-rich plaque [28][29][30] (reviewed in Nelson et al). 31 EPA and DHA are also converted to specialized proresolving lipid mediators, with EPA and DHA being the respective precursors of the E-series and D-series resolvins. 32 The resolvins have been shown to stimulate the resolution of acute inflammation by stopping further neutrophil recruitment to inflamed tissues and stimulating nonphlogistic infiltration of monocytes, which differentiate into resolution macrophages.…”
Section: Discussionmentioning
confidence: 99%
“…Lymphoid cells including DCs were also altered in HFHCD+CLA-treated mice. Many studies have investigated attenuation of disease progression using lipid mediators such as v-3 fatty acids (39,40), eicosapentaenoic acid (41), and lipid mediators maresin-1 and resolvin D2 (41). N-3 fatty acids had no effect on slowing progression of atherosclerosis in carotid arteries of patients (39) or in ApoE 2/2 mice, but they did attenuate lesion progression and reduce plasma cholesterol in LDL receptor knockout mice (40).…”
Section: Discussionmentioning
confidence: 99%
“…Eicosapentaenoic acid showed beneficial effects on plaque characteristics and lower plasma triglyceride levels without raising LDL cholesterol. Eicosapentaenoic acid in combination with a statin reduced 19% of major coronary artery events (41). Limited studies have used in vivo murine models, with only 1 study reporting successful prevention of disease progression in ApoE 2/2 mice using resolvin D2 and maresin-1 (42).…”
Section: Discussionmentioning
confidence: 99%
“…The effects of EPA on atherosclerotic plaque have been investigated in animal and clinical studies [32]. Preclinical data from animal models support beneficial effects of EPA on atherosclerotic lesions including stable morphology, reduction of established plaques, and decreased inflammation [33][34][35].…”
Section: Effects Of Epa On Plaquementioning
confidence: 99%